Simplicity is a virtue

From Washington, DC,

• The House of Representatives and the Senate return to Capitol Hill this week for Committee business and floor voting.

• Per a House notice,
  • “On Thursday, June 4, 2026, at 10:00 a.m. ET, the Subcommittee on Government Operations will hold a hearing titled “Hearing with the Commissioners of the Postal Regulatory Commission.” The hearing will convene in room 2154 of the Rayburn House Office Building.”

• Late Friday afternoon, the U.S. Office of Personnel Management placed on the Federal Register’s public inspection list an interim final rule on collection of family member status documentation proving eligibility for FEHB or PSHB coverage as a family member.
  • “The FEHB Protection Act of 2025 (FPA) requires OPM to issue regulations and implement a process to verify: The veracity of any qualifying life event (QLE) through which a health benefits plan enrollee seeks to add a member of family to their enrollment and that when an enrollee adds a family member to the health benefits plan, including during any open season, the individual is a qualified member of family. This final rule also clarifies responsibilities for initial family member eligibility determinations for the Postal Service Health Benefits (PSHB) Program.”

From the American Society of Clincal Oncology’s annual meeting,

• The Wall Street Journal reports,
  • “Brain tumors are one of the most devastating consequences of cancer’s spread—hard to treat and highly deadly. Scientists have found that using a radioactive implant precisely where a tumor was removed in the brain can help patients get their cancer treated more quickly and in many cases, live longer.
  • “A new study showed that GammaTile, a radioactive wafer the size of a postage stamp, nearly doubled survival rates and nearly eliminated tumor regrowth in people who had it placed in the spot where brain tumors were surgically removed.
  • “Between 100,000 and 200,000 Americans a year are diagnosed with cancer so advanced it has spread to the brain. Typically, patients get those tumors surgically removed and follow up with radiation therapy from a device outside of their body, rather than from within it.
  • “The tiles are already cleared by the Food and Drug Administration. Until this study, which will be presented at the American Society of Clinical Oncology annual meeting this weekend, no large randomized trial had shown that they worked better than the traditional approach for these types of brain tumors.
  • In the new study, involving 230 people, nearly two-thirds of those given the tiles were alive two years later, compared with around a third of those who got standard radiation after surgery. Tumors grew back at the surgical site in just 1% of patients who got the implants, versus 12% of those who got the standard treatment.
  • “That survival difference is pretty astonishing,” said Dr. Molly Blau, a radiation oncologist at Fred Hutch Cancer Center in Seattle who wasn’t involved in the study. Blau said the results could fuel conversations with surgeons at her institution about investing in a GammaTile program.”

• BioPharma Dive relates,
  • “An experimental drug from Revolution Medicines has proven broadly effective against an aggressive and tough-to-treat pancreatic tumor in a highly anticipated study result that could quickly change medical practice. 
  • “Revolution disclosed in April that the drug, daraxonrasib, nearly doubled survival compared to standard chemotherapy in a Phase 3 trial. At the American Society of Clinical Oncology meeting on Sunday, study investigators provided fuller details experts described as “unprecedented” and “landscape changing.”
  • Revolution’s primary study objective was to test whether daraxonrasib could benefit pancreatic cancer patients whose disease had spread despite a previous treatment and whose tumors were driven by a particular “RAS G12” mutation. But it also evaluated daraxonrasib’s effects on the entire trial population as a secondary outcome, too.
  • “Data presented at ASCO show Revolution’s drug extended survival by a median of 13.2 months among all recipients. By comparison, those who got chemotherapy and had RAS G12 mutations lived a median of 6.6 months. And that figure was comparable — 6.7 months — for all treated with chemo. 
  • “The benefits were similarly stark on measures of disease progression. For people with a RAS G12 mutation, daraxonrasib held tumors in check for a median of 7.3 months. For all drug recipients, that number was 7.2 months. Both numbers doubled the 3.5 month and 3.6 month median survival observed, respectively, among those groups of chemo recipients. 
  • “These results are landscape-changing for metastatic pancreatic cancer patients with a KRAS mutation,” said Rachna Shroff, hematology and oncology chief at the University of Arizona Cancer Center, in a statement provided by ASCO. “We are seeing unprecedented survival and efficacy in second-line treatment with an expected safety profile.”  
• and
  • “A double-barreled cancer immunotherapy extended the lives of people with lung cancer in a closely watched trial that’s viewed as important for gauging the potential impact of the drug, known as ivonescimab, as well as others like it. 
  • “Presented at the American Society of Clinical Oncology meeting Sunday, the findings come from a study testing ivonescimab in patients newly diagnosed with advanced, non-small cell lung cancer. Though run only in China, the study is a proxy for a global trial that could be worth tens of billions of dollars to the drug’s developers, Akeso and Summit Therapeutics. Like that global study, the China trial is testing an ivonescimab-chemotherapy combination against the kind of immunotherapy-chemo regimen that’s standard care for many new patients. 
  • “Last year, Akeso and Summit revealed that the ivonescimab regimen reduced the risk of disease progression by 40% when compared to chemo and an immunotherapy called Tevimbra. But they hadn’t yet disclosed whether the drug regimen extended lives, the gold standard for a cancer medicine. 
  • “Success in that objective carries implications not only for Akeso and Summit, but many others developing medicines like ivonescimab, which are known as “PD-1/VEGF inhibitors” because of the two proteins they target. These drugs have shown the potential to top widely used immunotherapies like Keytruda, sparking hope that they may become future cornerstones of cancer care. But modest results in some studies have stirred debate about their additive benefits.
  • “Heading into the ASCO presentation, multiple Wall Street analysts pegged a reduction in death risk of anywhere from 20% to 30% as indicative of a meaningful benefit. Ivonescimab hit that mark, with investigators disclosing Sunday that drug recipients lived a median of 28 months after enrollment, versus 24 months for the control group — a 34% relative risk reduction that was statistically significant.” 

• Fierce Pharma tells us,
  • “With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap.
  • “For patients with high-risk localized or locally advanced prostate cancer, surgical removal of the prostate (radical prostatectomy) is a key standard treatment alongside radiation therapy. But nearly half of patients who move forward with curative-intent surgery ultimately see their cancer return, requiring additional treatment and potentially missing the window in which a cure is possible.  
  • “Additional therapies often intervene only after the cancer has spread, limiting the chance to improve long-term outcomes. This has been the status quo essentially since the prostatectomy was introduced 125 years ago in 1904, J&J’s U.S. president of oncology for solid tumors, Biljana Naumovic, M.D., told Fierce in an interview on the sidelines of the 2026 American Society of Clinical Oncology (ASCO) annual meeting.”
  • “With its phase 3 Proteus study, J&J sought a solution—a way to meet the “one chance for curing this patient,” Mark Wildgust, Ph.D., J&J’s VP of global medical affairs for oncology, said in the joint interview. 
  • “In Proteus, when Erleada was given to patients with high-risk localized or locally advanced disease alongside hormone therapy (androgen deprivation therapy or ADT) for six months before and after surgery, the drug was able to provide significant improvements in “key short- and long-term clinical outcomes,” the company said in a May 31 release. 
  • “Patients who used Erleada and hormone therapy were nine times more likely to have “little to no” cancer remaining at the time of surgery compared with those on hormone therapy alone, with the treatment arm linked to a 8.9% rate of pathologic complete response/minimal residual disease compared to 1% among the hormone therapy-only group, the company said.
  •  “The regimen also reduced the risk of developing metastasis or death by 20% and extended the time before patients required additional therapy to more than six years, J&J reported. That latter figure nearly doubled the three and a half years experienced by those on hormone therapy alone.” 
    

From the U.S. healthcare business and artificial intelligence front,

• MedCity News reports,
  • “Garner Health, a digital platform connecting patients with high-performing providers, announced Thursday that it has raised $100 million in Series E funding.
  • “The company serves employers and has a dataset of over 60 billion medical records that helps identify the best quality doctors. When members choose high-performing providers through Garner’s dataset, their employer then covers most or all of their out-of-pocket costs. This incentivizes employees to choose better doctors and lowers costs for employers by avoiding unnecessary procedures.
  • ‘This comes at a time when the “cost crisis” for employers is especially acute, according to Nick Reber, Garner Health CEO.” 

• BioPharma News relates,
  • “Pfizer is the latest multinational pharmaceutical firm to turn to China for help discovering new medicines, striking late Thursday an expansive alliance with Innovent Biologics potentially worth more than $10 billion.
  • “The deal involves up to 12 cancer drugs, eight of which are early-stage prospects from Innovent, while the remaining four are “Pfizer-proposed” discovery programs. All are newer types of “antibody-drug conjugates” or “multispecific” antibodies — technologies that are becoming more popular in treating cancer.
  • “Innovent will handle discovery work and early research, with Pfizer taking over global development after Phase 1 testing. Pfizer will get worldwide rights, and cover all the costs for four programs. It’ll gain ownership outside of greater China to another four of those drugs, and then will equally split rights and development costs with Innovent on the other four prospects in the deal.
  • “All told, Innovent is receiving $650 million up front and is eligible for another $9.85 billion in downstream payouts should a variety of milestones be met. The Suzhou, China-based company would get royalties on the sales of any approved medicines emerging from the deal, too.” * * *
  • “These deals are causing consternation in biotech circles and sounding alarm bells in Washington D.C., as they’ve threatened the U.S.’ long-held edge and given China growing influence over pharmaceutical development. Yet they’ve continued apace without interference and, of late, have started to broaden in scope, with companies in China and the U.S. forming pacts that cater to their respective advantages, discovering medicines and selling them globally.”
    
• Beckers Health IT tells us,
  • “Microsoft has launched a preview version of Copilot Health, an AI-powered platform that allows users to aggregate health records, wearable device data and other personal health information in one place.
  • “The tool is available to U.S. users ages 18 and older who subscribe to Microsoft 365 Personal, Family or Premium plans. Users can access the platform through Copilot’s web interface using a consumer account.
  • “According to a May 29 Microsoft news release, Copilot Health enables users to build personal health profiles, connect Apple Health data and access records from more than 50,000 U.S. provider organizations.
  • “Microsoft said the platform can answer health-related questions, provide personalized insights based on users’ health information and help users identify healthcare providers by specialty, language, insurance coverage and location.
  • “Microsoft said health conversations within Copilot Health are kept separate from other Copilot interactions and are not used to train AI models. Users can manage or remove connected health data sources, and information is encrypted in storage and during transmission.”